Biosimilars: Are you generating the right real-world evidence to influence the right stakeholders?

As the biosimilar sector continues to evolve and experience of their use deepens, what role should real-world data (RWE) now take in stakeholder communications? Focusing RWE that supports health decisions is vital so which stakeholders should be the target of your RWE strategy, what evidence do they want and, more importantly, what data sources will deliver? In Biosimilars: The Importance of Real World Evidence experienced industry experts from companies such as Sandoz, Avalere and Biogen share their thought and insights on the practical issues and challenges of cost effectively generating powerful RWE that really drives physician understanding and patient confidence.

Find out more >>